Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. - Petrova MP; Donev IS; Radanova MA; Eneva MI; Dimitrova EG; Valchev GN; Minchev VT; Taushanova MS; Boneva MV; Karanikolova TS; Gencheva RB; Zhbantov GA; et al. (Clinical and experimental immunology, 2020)